Fecha de la publicación: 06/03/2020
Autor: Lucia Beltran-Camacho 1 2, Margarita Jimenez-Palomares 1 2, Marta Rojas-Torres 1 2, Ismael Sanchez-Gomar 1 2, Antonio Rosal-Vela 1 2, Sara Eslava-Alcon 1 2, Mª Carmen Perez-Segura 1, Ana Serrano 1, Borja Antequera-González 1 2, Jose Angel Alonso-Piñero 1 2, Almudena González-Rovira 1 2, Mª Jesús Extremera-García (1, 2), Manuel Rodriguez-Piñero (3), Rafael Moreno-Luna (4), Martin Røssel Larsen (5), Mª Carmen Durán-Ruiz (6, 7)
1Biomedicine, Biotechnology and Public Health Department, Cádiz University, Cadiz, Spain.
2Institute of Biomedical Research Cadiz (INIBICA), Cadiz, Spain.
3Angiology & Vascular Surgery Unit, Hospital Universitario Puerta del Mar, Cádiz, Spain.
4Laboratory of Neuroinflammation, Hospital Nacional de Paraplejicos, SESCAM, Toledo, Spain.
5Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark.
6Biomedicine, Biotechnology and Public Health Department, Cádiz University, Cadiz, Spain. email@example.com.
7Institute of Biomedical Research Cadiz (INIBICA), Cadiz, Spain. firstname.lastname@example.org.
Background: Critical limb ischemia (CLI) constitutes the most aggressive form of peripheral arterial occlusive disease, characterized by the blockade of arteries supplying blood to the lower extremities, significantly diminishing oxygen and nutrient supply. CLI patients usually undergo amputation of fingers, feet, or extremities, with a high risk of mortality due to associated comorbidities. Circulating angiogenic cells (CACs), also known as early endothelial progenitor cells, constitute promising candidates for cell therapy in CLI due to their assigned vascular regenerative properties. Preclinical and clinical assays with CACs have shown promising results. A better understanding of how these cells participate in vascular regeneration would significantly help to potentiate their role in revascularization. Herein, we analyzed the initial molecular mechanisms triggered by human CACs after being administered to a murine model of CLI, in order to understand how these cells promote angiogenesis within the ischemic tissues.
Methods: Balb-c nude mice (n:24) were distributed in four different groups: healthy controls (C, n:4), shams (SH, n:4), and ischemic mice (after femoral ligation) that received either 50 μl physiological serum (SC, n:8) or 5 × 105 human CACs (SE, n:8). Ischemic mice were sacrificed on days 2 and 4 (n:4/group/day), and immunohistochemistry assays and qPCR amplification of Alu-human-specific sequences were carried out for cell detection and vascular density measurements. Additionally, a label-free MS-based quantitative approach was performed to identify protein changes related.
Results: Administration of CACs induced in the ischemic tissues an increase in the number of blood vessels as well as the diameter size compared to ischemic, non-treated mice, although the number of CACs decreased within time. The initial protein changes taking place in response to ischemia and more importantly, right after administration of CACs to CLI mice, are shown.
Conclusions: Our results indicate that CACs migrate to the injured area; moreover, they trigger protein changes correlated with cell migration, cell death, angiogenesis, and arteriogenesis in the host. These changes indicate that CACs promote from the beginning an increase in the number of vessels as well as the development of an appropriate vascular network.